# A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

> **NCT03060629** · PHASE2 · TERMINATED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 2636 (actual)

## Conditions studied

- HIV-1

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV
- **BIOLOGICAL:** Clade C gp140
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03060629
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-03
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-02-02
- **Target enrollment:** 2636 (ACTUAL)
- **Why stopped:** Study was terminated by the sponsor after the last participant completed the Month 24 visit as the pre-specified criteria to continue the study were not met.
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060629, "A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03060629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*